Cabozantinib-induced thyroid dysfunction: A review of two ongoing trials for metastatic bladder cancer and sarcoma

Thyroid

Volumn 24, Issue 8, 2014, Pages 1223-1231

  Yavuz, Sahzene ^a   Apolo, Andrea B ^b   Kummar, Shivaani ^b   Del Rivero, Jaydira ^c   Madan, Ravi A ^b   Shawker, Thomas ^d   Reynolds, James ^d   Celi, Francesco S ^a,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; DASATINIB; IBUPROFEN; LEVOTHYROXINE; LIOTRIX; NILOTINIB; PREDNISONE; PROPRANOLOL; SORAFENIB; SUNITINIB; ANILIDE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ADULT; AGED; BLADDER CANCER; BLADDER METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE STUDY; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; MALE; MEDLINE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SUBCLINICAL HYPOTHYROIDISM; SYSTEMATIC REVIEW (TOPIC); THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOPPLER FLOWMETRY; ECHOGRAPHY; NEOPLASM METASTASIS; PATHOPHYSIOLOGY; SARCOMA; THYROID DISEASES; THYROID GLAND; URINARY BLADDER NEOPLASMS;

ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; PYRIDINES; SARCOMA; THYROID DISEASES; THYROID GLAND; THYROTOXICOSIS; ULTRASONOGRAPHY, DOPPLER; URINARY BLADDER NEOPLASMS;

EID: 84904695352     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0621     Document Type: Review

References (39)

1. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336.
2. Torino F, Barnabei A, Paragliola RM, Baldelli R, Appetecchia M, Corsello SM 2013 Thyroid as unintended side effect of anticancer drugs. Thyroid 23:1345-1366.
3. Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S, Nakamura H 2012 Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 23:443-448.
4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664. (Pubitemid 46768841)
5. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K 2011 The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104:241-247.
6. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG,Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268. (Pubitemid 351201706)
7. Clement P Wolter P, Stefan C, Decallonne B, Dumez H, Wildiers H, Schöffski P 2008 Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. [Abstract] J Clin Oncol 26(15S):16145.
8. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, Braun D, Schweizer U, Arnold R, Dörken B, le Coutre P 2010 Thyroid dysfunction caused by secondgeneration tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20:1209-1214.
9. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ 2011 Sunitinibinduced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087-3094.
10. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schoffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454.
11. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, Bladou F, Gravis G 2012 Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol 23:714-721.
12. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 28:515-519.
13. Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T 2012 Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 42:742-747.
14. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H 2010 Effect of axitinib (AG - 013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101:963-968.
15. Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group 2011 Key predictive factors of axitinib (AG-013736)- induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 47:2592-2602.
16. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP 2011 Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21:197-202.
17. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology 69:669-672.
18. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)- induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149. (Pubitemid 350207759)
19. Sakurai K, Fukazawa H, Arihara Z, Yoshida K 2010 Sunitinib- induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 222:39-44.
20. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L 2010 Sorafenib-induced destructive thyroiditis. Thyroid 20:1043-1044.
21. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L 2008 Sunitinib associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809-812. (Pubitemid 352009925)
22. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534. (Pubitemid 47435331)
23. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355. (Pubitemid 46776140)
24. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E, Romijn JA, Visser TJ, Smit JW 2010 Sorafenib-Induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 95:3758-3762.
25. Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM, Schweizer U 2012 Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 97:E100-E105.
26. Makita N, Miyakawa M, Fujita T, Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20:323-326.
27. Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y 2010 Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57:873-880.
28. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP 2005 Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438. (Pubitemid 41393678)
29. Liwanpo L, Hershman JM 2009 Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 23:781-792.
30. Makita N, Iiri T 2013 Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23:151-159.
31. Bianchi L, Rossi L, Tomao F, Papa A, Zoratto F, Tomao S 2013 Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma Endocr Relat Cancer 20:R233-R245.
32. Samuels MH 2012 Subacute, silent, and postpartum thyroiditis Med Clin North Am 96:223-233.
33. Vetter ML, Kaul S, Iqbal N 2008 Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract 14:618-624.
34. Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K 2012 Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Eur J Radiol 81:2060-2065.
35. Rogiers A,Wolter P, Op de Beeck K, ThijsM, Decallonne B, Schöffski P 2010 Shrinkage of thyroid volume in sunitinibtreated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317-322.
36. Meller J, Becker W 1999 Scintigraphy with 99mTcpertechnetate in the evaluation of functional thyroidal autonomy. Q J Nucl Med 43:179-187. (Pubitemid 29500574)
37. Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S 2008 The usefulness of 99m Tc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodaroneinduced thyrotoxicosis. Eur J Endocrinol 159:423-429.
38. Brian SR, Cheng DW, Goldberg PA 2007 Unusual case of amiodarone-induced thyrotoxicosis: "illicit" use of a technetium scan to diagnose a transiently toxic thyroid nodule. Endocr Pract 13:413-416.
39. Hiromatsu Y, Ishibashi M, Miyake I, Soyejima E, Yamashita K, Koike N, Nonaka K 1999 Color Doppler ultrasonography in patients with subacute thyroiditis. Thyroid 9:1189. Kidney Diseases